Table 4.
Summary results for SNV-eGFRcreatinine analyses in UKBB (model 1).
| Genetic variant (EA) | EAF | Population ** | N | Effect (Beta [SE]) | P-value |
|---|---|---|---|---|---|
| rs144360241 (C) | 0.004 | NDM *** | 369,832 | 0.008 (0.002) | 0.0008* |
| 0.004 | T2D **** | 14,882 | 0.02 (0.02) | 0.23 | |
| rs45551835 (A) | 0.014 | NDM *** | 369,028 | 0.005 (0.001) | 0.0004* |
| 0.014 | T2D **** | 14,860 | 0.01 (0.01) | 0.13 | |
| rs141640975 (A) | 0.003 | NDM *** | 369,987 | 0.02 (0.003) | 2.2 × 10-9* |
| 0.003 | T2D **** | 14,885 | -0.01 (0.02) | 0.71 | |
| rs1801239 (C) | 0.10 | NDM *** | 369,849 | 0.001 (0.0005) | 0.006* |
| 0.10 | T2D **** | 14,880 | 0.00 (0.00) | 0.42 |
SNV, single-nucleotide variant; eGFRcreatinine, estimated glomerular filtration rate (natural log-transformed); EA, effect allele (i.e., minor allele); N, sample size; EAF, Effect allele frequency; Beta, Beta coefficient; SE, standard error; NDM, without Diabetes Mellitus; T2D, Type 2 diabetes. *Statistically significant (P< 0.05). ** For completeness, we also show the results for T2D, which were part of DM meta-analyses for model 1. *** out of total 370,061 individuals. **** out of total 14,892 individuals.